What should I avoid while taking Isradipine 2.5mg tablets?

Take with or without food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Isradipine 2.5mg tablets?

Isradipine 2.5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Isradipine 2.5mg tablets?

Isradipine 2.5mg tablets is the generic name. It is available under brand names including: Isradipine 2.5mg tablets, Isradipine 2.5mg tablets, Isradipine 2.5mg tablets, Isradipine 2.5mg tablets, Prescal 2.5mg tablets and 6 more. (Source: NHS dm+d — Actual Medicinal Products)

Isradipine 2.5mg tablets

Tablet

2.5mg

Oral

Antihypertensive

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs.

Active ingredients:

Isradipine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.06.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C08CA03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Check interactions for Isradipine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Isradipine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Isradipine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Isradipine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

11 branded products available

11 productsShow details

11 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Isradipine on the MHRA register

Prescal 2.5mg tablets

Novartis Pharmaceuticals UK Ltd

Discontinued

Prescal 2.5mg tablets

Dowelhurst Ltd

Discontinued

Prescal 2.5mg tablets

DE Pharmaceuticals

Discontinued

Prescal 2.5mg tablets

Sigma Pharmaceuticals Plc

Discontinued

Prescal 2.5mg tablets

Lexon (UK) Ltd

Discontinued

Prescal 2.5mg tablets

Mawdsley-Brooks & Company Ltd

Discontinued

Prescal 2.5mg tablets

Waymade Healthcare Plc

Discontinued

Isradipine 2.5mg tablets

Sandoz Ltd

Discontinued

Isradipine 2.5mg tablets

Alliance Healthcare (Distribution) Ltd

Discontinued

Isradipine 2.5mg tablets

A A H Pharmaceuticals Ltd

Discontinued

Isradipine 2.5mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

5 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Amlodipine 2.5mg tablets

Tablet

2.5mg

Same therapeutic group

Lacidipine 6mg tablets

Tablet

6mg

Same therapeutic group

Amlodipine 5mg/5ml oral suspension sugar free

Oral suspension

5mg/5ml

Same therapeutic group

Nimodipine 60mg/5ml oral suspension

Oral suspension

60mg/5ml

Same therapeutic group

Felodipine 2.5mg/5ml oral suspension

Oral suspension

2.5mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Isradipine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Isradipine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42212711000001106

dm+d ID

42212711000001106

VTM (Virtual Therapeutic Moiety)

776431008

VMP (Virtual Medicinal Product)

42212711000001106

BNF code

02060200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C08CA03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

26 found

Half-life

8 hours

Mechanism

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blocker…

Food interactions

1 warning

Human targets

7 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

90%

Isradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.

Half-life

8 hours

8 hours

Protein binding

95%

Metabolism

Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine.

Elimination

60%

Approximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.

Properties:

solid

Avg. mass: 371.39 Da

DrugBank indication

For the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.

Also known as(51)

Isradipine

Isradipino

Isradipinum

CACH2

CACN2

CACNL1A1

Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle

CCHL1A1

Dosage forms(11)

Tablet (Oral) — 2.5 mg

Capsule (Oral) — 2.5 mg/1

Capsule (Oral) — 5 mg/1

Tablet, film coated, extended release (Oral) — 10 mg/1

Tablet, film coated, extended release (Oral) — 5 mg/1

Tablet (Oral) — 0.0025 g

Capsule, coated (Oral) — 5 mg

Capsule, extended release (Oral)

Molecular properties(19)

Drug interactions(2071)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Isradipine is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Isradipine is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Isradipine may increase the hypotensive activities of Risperidone.

Check this interaction

Troglitazone

Moderate

DB00197

Troglitazone may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Reserpine

Moderate

DB00206

Reserpine may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Progesterone

Moderate

DB00396

Progesterone may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Chlorpromazine

Moderate

DB00477

Chlorpromazine may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Bosentan

Moderate

DB00559

Bosentan may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Ethinylestradiol

Moderate

DB00977

Ethinylestradiol may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Glyburide

Moderate

DB01016

Glyburide may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Fusidic acid

Moderate

DB02703

Fusidic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Simeprevir

Moderate

DB06290

Simeprevir may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Lenvatinib

Moderate

DB09078

Lenvatinib may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Pralsetinib

Unknown severity

DB15822

The serum concentration of Pralsetinib can be increased when it is combined with Isradipine.

Check this interaction

Ceritinib

Moderate

DB09063

Isradipine may increase the bradycardic activities of Ceritinib.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Isradipine.

Check this interaction

Amifostine

Moderate

DB01143

Isradipine may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Isradipine.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Isradipine.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Isradipine.

Check this interaction

Obinutuzumab

Moderate

DB08935

Isradipine may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Isradipine.

Check this interaction

Rituximab

Moderate

DB00073

Isradipine may increase the hypotensive activities of Rituximab.

Check this interaction

Isoetharine

Moderate

DB00221

Isoetharine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Zolmitriptan

Moderate

DB00315

Zolmitriptan may decrease the antihypertensive activities of Isradipine.

Check this interaction

Norepinephrine

Moderate

DB00368

Norepinephrine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Phenylpropanolamine

Moderate

DB00397

Phenylpropanolamine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Isradipine.

Check this interaction

Metaraminol

Moderate

DB00610

Metaraminol may decrease the antihypertensive activities of Isradipine.

Check this interaction

Methoxamine

Moderate

DB00723

Methoxamine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Orciprenaline

Moderate

DB00816

Orciprenaline may decrease the antihypertensive activities of Isradipine.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Pseudoephedrine

Moderate

DB00852

Pseudoephedrine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Ritodrine

Moderate

DB00867

Ritodrine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Bitolterol

Moderate

DB00901

Bitolterol may decrease the antihypertensive activities of Isradipine.

Check this interaction

Diethylpropion

Moderate

DB00937

Diethylpropion may decrease the antihypertensive activities of Isradipine.

Check this interaction

Naratriptan

Moderate

DB00952

Naratriptan may decrease the antihypertensive activities of Isradipine.

Check this interaction

Frovatriptan

Moderate

DB00998

Frovatriptan may decrease the antihypertensive activities of Isradipine.

Check this interaction

Isoprenaline

Moderate

DB01064

Isoprenaline may decrease the antihypertensive activities of Isradipine.

Check this interaction

Arbutamine

Moderate

DB01102

Arbutamine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Lisdexamfetamine

Moderate

DB01255

Lisdexamfetamine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Fenoterol

Moderate

DB01288

Fenoterol may decrease the antihypertensive activities of Isradipine.

Check this interaction

Pirbuterol

Moderate

DB01291

Pirbuterol may decrease the antihypertensive activities of Isradipine.

Check this interaction

Ephedra sinica root

Moderate

DB01363

Ephedra sinica root may decrease the antihypertensive activities of Isradipine.

Check this interaction

Ephedrine

Moderate

DB01364

Ephedrine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Mephentermine

Moderate

DB01365

Mephentermine may decrease the antihypertensive activities of Isradipine.

Check this interaction

Showing 50 of 2071 interactions

Food & lifestyle interactions

Advice

Take with or without food.

Toxicity & overdose

Symptoms of overdose include lethargy, sinus tachycardia, and transient hypotension. Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival.

How it works

Mechanism of action

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, isradipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives isradipine additional arterial selectivity. At therapeutic sub-toxic concentrations, isradipine has little effect on cardiac myocytes and conduction cells.

Pharmacodynamics

Isradipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of isradipine result in an overall decrease in blood pressure.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Isradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.

Half-life

8 hours

Protein binding

95%

Metabolism

Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine.

Route of elimination

Approximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces.

Drug targets(7)

Proteins and enzymes this drug interacts with in the body

Voltage-dependent L-type calcium channel subunit alpha-1C

BE0000430

CACNA1C

inhibitor

Specific functionalpha-actinin binding

Cellular location

Cell membrane

General function & pharmacology

Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents .
PMID:12181424 PMID:15454078 PMID:15863612 PMID:16299511 PMID:17224476 PMID:20953164 PMID:23677916 PMID:24728418 PMID:26253506 PMID:27218670 PMID:29078335 PMID:29742403 PMID:30023270 PMID:30172029 PMID:34163037 PMID:8099908

Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm .
PMID:15454078 PMID:15863612 PMID:17224476 PMID:24728418 PMID:26253506

Required for normal contraction of smooth muscle cells in blood vessels and in the intestine.

Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells .
PMID:28119464
Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable)

Voltage-dependent calcium channel subunit alpha-2/delta-1

BE0000691

CACNA2D1

inhibitor

Specific functionmetal ion binding

Cellular location

Membrane

General function & pharmacology

The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel .
PMID:35293990
Plays an important role in excitation-contraction coupling (By similarity)

Voltage-dependent L-type calcium channel subunit beta-2

BE0002354

CACNB2

inhibitor

Specific functionactin filament binding

Cellular location

Cell membrane, sarcolemma

General function & pharmacology

Beta subunit of voltage-dependent calcium channels which contributes to the function of the calcium channel by increasing peak calcium current (By similarity). Plays a role in shifting voltage dependencies of activation and inactivation of the channel (By similarity). May modulate G protein inhibition (By similarity).

May contribute to beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force .
PMID:36424916
Involved in membrane targeting of the alpha-1 subunit CACNA1C PMID:17525370

Voltage-dependent T-type calcium channel subunit alpha-1H

BE0000864

CACNA1H

inhibitor

Specific functionlow voltage-gated calcium channel activity

Cellular location

Cell membrane

General function & pharmacology

Voltage-sensitive calcium channel that gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group. A particularity of this type of channel is an opening at quite negative potentials, and a voltage-dependent inactivation .
PMID:27149520 PMID:9670923 PMID:9930755

T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle (Probable).

They may also be involved in the modulation of firing patterns of neurons .
PMID:15048902
In the adrenal zona glomerulosa, participates in the signaling pathway leading to aldosterone production in response to either AGT/angiotensin II, or hyperkalemia PMID:25907736 PMID:27729216

Voltage-dependent calcium channel subunit alpha-2/delta-2

BE0002396

CACNA2D2

inhibitor

Specific functionmetal ion binding

Cellular location

Membrane

General function & pharmacology

The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G) .
PMID:15111129 PMID:23339110
Overexpression induces apoptosis

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

Bile salt export pump

BE0000703

ABCB11

substrate

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

Biological pathways(1)

Isradipine Action Pathway

Involved compounds

ATP,Calcium,Isradipine,Magnesium cation,Potassium cation

Scientific references(4)

Fletcher H., Roberts G., Mullings A., Forrester T.

An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia.

Journal of Obstetrics and Gynaecology

199919(3):235-238. doi: 10.1080/01443619964977

PMID: 15512286 DOI: 10.1080/01443619964977

Ganz M., Mokabberi R., Sica D.A.

Comparison of Blood Pressure Control With Amlodipine and Controlled‐Release Isradipine: An Open‐Label, Drug Substitution Study.

The Journal of Clinical Hypertension

20057(s4):27-31. doi: 10.1111/j.1524-6175.2005.04450.x

PMID: 15858400 DOI: 10.1111/j.1524-6175.2005.04450.x

Hattori T., Wang P.L.

Control of Cell Function by Neuronal Calcium-Activated Nonselective (CAN) Cation Channels. Nonselective Cation Channels. 1993;:175-183.

doi: 10

1007/978-3-0348-7327-7_13

PMID: 16751108 DOI: 10.1007/978-3-0348-7327-7_13

Johnson B.A., Roache J.D., Ait-Daoud N., Wallace C., Wells L., Dawes M., Wang Y.

Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects.

The International Journal of Neuropsychopharmacology

20058(2):203-213. doi: 10.1017/s1461145704005036

PMID: 15850499 DOI: 10.1017/s1461145704005036

ATC classification(1 code)

ATC C08CA03

Affected organisms(1)

Humans and other mammals

International brands(4)

Experimental properties(3)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(25)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Isradipine

DB00270

CAS number

75695-93-1

UNII (FDA)

YO1UK1S598

InChI Key (molecular fingerprint)

HMJIYCCIJYRONP-UHFFFAOYSA-N

Additional database identifiers

ChEBI

6073

PubChem Compound

3784

PubChem Substance

46505034

KEGG Drug

D00349

ChemSpider

3652

BindingDB

50436176

PharmGKB

PA450131

Therapeutic Targets Database

DAP000134

Wikipedia

Isradipine

ChEMBL

CHEMBL1648

RxCUI

33910

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1399

GenAtlas

CACNA2D1

GeneCards

CACNA2D1

GenBank Gene Database

M76559

GenBank Protein Database

179762

UniProtKB

P54289

UniProt Accession

CA2D1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1395

GenAtlas

CACNA1H

GeneCards

CACNA1H

GenBank Gene Database

AF051946

GenBank Protein Database

14670397

IUPHAR

536

Guide to Pharmacology

536

UniProtKB

O95180

UniProt Accession

CAC1H_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1400

GenAtlas

CACNA2D2

GeneCards

CACNA2D2

GenBank Gene Database

AJ251368

UniProtKB

Q9NY47

UniProt Accession

CA2D2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

International reference pricing

8 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $1.39/capsule

To $5.59/tablet

Isradipine 2.5 mg capsule

$1.39/capsule

DynaCirc 2.5 mg capsule

$1.59/capsule

Isradipine 5 mg capsule

$2.00/capsule

DynaCirc 5 mg capsule

$2.31/capsule

Dynacirc cr 5 mg tablet

$2.88/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Isradipine 2.5mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
10

Chemical identifiers

Isradipine

Additional database identifiers

International reference pricing

DrugBank citations

Isradipine 2.5mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science10

Chemical identifiers

Isradipine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
10